http://www-dep.iarc.fr. Accessed April 23, 2007.
(4) Jemal A et al. CA Cancer J Clin. 2007;57:43-66.
(5) The reported mortality of HCC in Europe is higher than the incidence
of HCC in Europe. This is due to the overestimation of mortality by
occasional counting of metastatic cancers that have spread to the
liver, and underestimation of incidence as a result of a lack of
technology for early detection and diagnosis of HCC. Source:
International Agency for Research on Cancer.
(6) Ferlay J, et al., GLOBOCAN 2002. Cancer Incidence, Mortality and
Prevalence Worldwide. IARC CancerBase No.5, Version 2.0. IARCPress,
Lyon, 2004. Available at: http://www-dep.iarc.fr. Accessed April 10,
(7) Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg
L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (eds).
SEER Cancer Statistics Review, 1975-2004, National Cancer Institute.
Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/, based on November
2006 SEER data submission, posted to the SEER web site, 2007.
(8) American Cancer Society. Cancer Facts & Figures 2007. Atlanta:
American Cancer Society: 2007.
|SOURCE Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals,Inc.
Copyright©2007 PR Newswire.
All rights reserved